Investigating the efficacy of bioactive compounds of the bitter orange plant on uremic pruritus using molecular docking study

Ziari, Mitra; Habibzadeh, Sepideh; Didehban, Khadijeh; Mardani, Hamidreza

doi:10.22036/cr.2022.345196.1190

Investigating the efficacy of bioactive compounds of the bitter orange plant on uremic pruritus using molecular docking study

Document Type : Original Article

Authors

mitra ziari ¹

sepideh habibzadeh ²

khadijeh didehban ¹

hamidreza mardani ¹

¹ payame noor university

² Department of Chemistry, Payame Noor University, Tehran, Iran

10.22036/cr.2022.345196.1190

Abstract

Uremic pruritus is a frequent symptom in patients with chronic kidney disease, which affects about one-third of dialysis patients and greatly reduces their quality of life. Using drugs derived from natural plants can be an alternative way to limit and treat uremic pruritus in kidney patients. This research was conducted to evaluate the antipruritic potential of bioactive compounds of Bitter orange. A molecular docking simulation was performed on the nine natural components of Bitter orange against the active binding sites of four protein receptors related to the itching mechanism. The results showed that the selected compounds could inhibit kappa-opioid receptors 4DJH, 6VI4, 6B73, and G protein-coupled receptor 5ZTY well and have a stronger inhibitory effect compared to the anti-itch drug Gabapentin. According to the binding scores (DS) ranging from -8.72 to -4.88, and inhibition constants (Ki), the best antipruritic activities belong to Nobiletin, Caryophyllene, Naringenin, and Tangeretin ligands. The binding results showed that the natural compounds of orange could be considered a valuable source for inhibiting uremic pruritus.

Graphical Abstract

Investigating the efficacy of bioactive compounds of the bitter orange plant on uremic pruritus using molecular docking study

Keywords

Antipruritic

Bioactive compounds

Bitter orange

Molecular docking

Uremic pruritus

[1] R. Feldman. N. Berman. M. C. Reid. J. Roberts. R. Shengelia. K. Christianer. B. Eiss, R. D. Adelman, Journal of Palliative Medicine 16 (2013) 1528.

[2] S. D. Weisbord. L. F. Fried. M. K. Mor. A. L. Resnick. M. L. Unruh. P. M. Palevsky. D. J. Levenson. S. H. Cooksey. M. J. Fine, P. L. Kimmel, Clinical Journal of the American Society of Nephrology 2 (2007) 960.

[3] E. Weisshaar. U. Matterne, T. Mettang, Nephrology Dialysis Transplantation 24 (2009) 1328.

[4] T. Lau. S. Leung, W. Lau, Canadian Journal of Kidney Health and Disease 3 (2016) 1.

[5] R. L. Pisoni. B. Wikström. S. J. Elder. T. Akizawa. Y. Asano. M. L. Keen. R. Saran. D. C. Mendelssohn. E. W. Young, F. K. Port, Nephrology Dialysis Transplantation 21 (2006) 3495.

[6] L. Manenti. P. Tansinda, A. Vaglio, Drugs 69 (2009) 251.

[7] T. Mettang, A. E. Kremer, Kidney international 87 (2015) 685.

[8] N. Z. Sepehri. M. M. Parvizi. S. Habibzadeh, F. Handjani, Evidence-Based Complementary and Alternative Medicine 2022 .

[9] P.-Y. Tseng, M. A. Hoon, The Kappa Opioid Receptor 271 (2020) 255.

[10] M. Uma, Journal of Bioinformatics and Sequence Analysis 3 (2011) 6.

[11] K.-i. Kusakabe. Y. Iso. Y. Tada. M. Sakagami. Y. Morioka. N. Chomei. S. Shinonome. K. Kawamoto. H. Takenaka, K. Yasui, Bioorganic & medicinal chemistry 21 (2013) 3154.

[12] S. A. Combs. J. P. Teixeira, M. J. Germain, Seminars in nephrology, Elsevier2015.

[13] M. Raouf. T. J. Atkinson. M. W. Crumb, J. Fudin, Journal of Pain Research 10 (2017) 275.

[14] R. Kaur, V. Sinha, European Neuropsychopharmacology 28 (2018) 341.

[15] A. Agrawal, G. T. Kulkarni, Indian Journal of Biochemistry & Biophysics 57 (2020) 578.

[16] D. Bagchi, H. G. Preuss, Obesity: epidemiology, pathophysiology, and prevention, CRC press2007.

[17] م. میرزایی. ش. خاکپور. م. خسروی, ص. اربابیان, فصلنامه علوم پزشکی دانشگاه آزاد اسلامی دوره ۲۲ (۱۳۹۱) ۱۰۱.

[18] A. Gurib-Fakim, Molecular aspects of Medicine 27 (2006) 1.

[19] N. Gholizade. Z. Khanbabapoor. F. Habibnejad. M. Lakzaei, M. Pouramir, Journal of Babol University of Medical Sciences 11 (2009) 7.

[20] م. ش. میمندی. ع. فرومدی. ش. رفتاری. م. ا. شکاری, م. محمودی, مجله علوم پزشکی کرمان ۱۲ (۱۳۸۴) ۲۴۴.

[21] ز. گلی. م. لکزایی, م. پورامیر, مجله علوم تغذیه و صنایع غذایی ایران ۵ (۱۳۸۹) ۱۹.

[22] M. Lakzaei. M. Pouramir. A. Moghadamnia, H. Mir, Journal of Babol University of Medical Sciences 14 (2012) 19.

[23] Y. Satoh. S. Tashiro. M. Satoh. Y. Fujimoto. J. Xu, T. Ikekawa, Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan 116 (1996) 244.

[24] P. B. Jadhav. A. R. Yadav, M. G. Gore, Int J Pharm Biol Sci 6 (2015) 142.

[25] https://pubchem.ncbi.nlm.nih.gov.

[26] J. Gasteiger, M. Marsili, Tetrahedron 36 (1980) 3219.

[27] https://www.rcsb.org.

[28] S. J. Weiner. P. A. Kollman. D. A. Case. U. C. Singh. C. Ghio. G. Alagona. S. Profeta, P. Weiner, Journal of the American Chemical Society 106 (1984) 765.

[29] A. Mojaddami. A. Sakhteman. M. Fereidoonnezhad. Z. Faghih. A. Najdian. S. Khabnadideh. H. Sadeghpour, Z. Rezaei, Research in pharmaceutical sciences 12 (2017) 21.

[30] S. Habibzadeh, M. E. Zohalinezhad, Biointerface Research in Applied Chemistry 12 (2021) 6382.

[31] S. Salentin. S. Schreiber. V. J. Haupt. M. F. Adasme, M. Schroeder, Nucleic acids research 43 (2015) W443.

[32] M. F. Adasme. K. L. Linnemann. S. N. Bolz. F. Kaiser. S. Salentin. V. J. Haupt, M. Schroeder, Nucleic acids research 49 (2021) W530.

[33] V. K. Vishvakarma. B. Nand. V. Kumar. K. Kumari. I. Bahadur, P. Singh, Computational Toxicology (Amsterdam, Netherlands) 16 (2020) 100140.

[34] A. Daina. O. Michielin, V. Zoete, Scientific reports 7 (2017) 1.

[35] https://www.swissadme.ch.

[36] A. Mehmood. S. Khan. S. Khan. S. Ahmed. A. Ali. M. Hamza. S. ur Rehman. A. M. Khan. A. H. Shah, Q. Bai, Saudi Journal of Biological Sciences 28 (2021) 3137.

[37] A. A. Parikesit, R. Nurdiansyah, Cermin Dunia Kedokteran 47 (2020) 222.

[38] A. Lagunin. A. Stepanchikova. D. Filimonov, V. Poroikov, Bioinformatics 16 (2000) 747.

[39] http://www.way2drug.com/passonline.